Landos Biopharma, Inc.
NLRX1 ligands

Last updated:

Abstract:

Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat multiple conditions, including inflammatory, immune-mediated, and/or chronic inflammatory gastrointestinal diseases; systemic immune-mediated diseases; cancers; and infectious diseases.

Status:
Grant
Type:

Utility

Filling date:

1 May 2020

Issue date:

20 Jul 2021